

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB 3235-
Number: 0104
Estimated average
burden hours per
response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Brown Dennis M	2. Date of Event Requiring Statement (Month/Day/Year) 01/25/2013	3. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]
(Last) (First) (Middle) SUITE 720-999 WEST BROADWAY	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Scientific Officer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street) VANCOUVER, A2 V5Z 1K5		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned	

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,903,542 (1)	I	See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrants	02/01/2012	02/01/2017	Common Stock	500,000	\$ 0.5 (2)	I	See Footnote (3)
Warrants	10/03/2011	01/25/2014	Common Stock	100,000	\$ (4)	D	
Warrants	02/27/2012	01/25/2014	Common Stock	240,000	\$ (5)	D	
Options	02/01/2012	02/01/2022	Common stock	150,000	\$ 0.5 (2)	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Brown Dennis M SUITE 720-999 WEST BROADWAY	X	X	Chief Scientific Officer	

Signatures

/s/ Dennis Brown

02/15/2013

--Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Includes 1,253,542 shares of the Issuer's common stock owned directly by Reporting Person and 1,650,000 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares

(2) Actual exercise price is CAD\$0.50 (Canadian dollar). The price listed in this Form 3 is the American dollar equivalent as of February 11, 2013, at which time CAD\$0.50 exchanged into USD\$0.50.

(3) Owned by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares

(4) Through July 25, 2013 the exercise price of such remaining warrants is USD\$0.96. Thereafter through the expiration date the exercise price of such remaining warrants shall be USD \$1.20.

(5) Through July 25, 2013 the exercise price of such remaining warrants is USD\$0.96. Thereafter through the expiration date the exercise price of such remaining warrants shall be USD \$1.20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.